

Harvard, Astellas establish strategic research alliance

01 May 2020 | News

Collaboration supports advancement of Harvard biomedical research and Astellas drug discovery research in a range of therapeutic areas



Harvard University and Japanese firm Astellas Pharma Inc. have established a three-year strategic research alliance to support multiple, multi-year research projects initiated by faculty at Harvard, focused on the research and development of innovative therapeutics and technologies of mutual interest.

The alliance will provide crucial support to future collaborative research efforts when the academic laboratories return to regular activities following the significant disruptions of the coronavirus pandemic.

Under the new alliance, Astellas will issue one or more “challenges” based on Astellas’ research scopes to inspire research proposals by Harvard faculty, a number of which will then be selected by Astellas for project funding based on strong scientific rationale and projected impact on value for patients.

Projects may span a range of developmental stages, from early investigations into the biological mechanisms of disease, to the identification of possible therapeutic targets, or to the generation and validation of new therapeutic entities.